Summary
The clinical trial which was done has shown only comparable efficacy to available treatment for positive symptoms. It did not study efficacy for cognition or negative symptoms. It did not test efficacy in treatment resistant patients. It did not show long term efficacy. It did not show that in combination with existing treatments it adds efficacy.
Analysis
Other companies will develop comparable compounds. There are many other very promising mechanisms that small and large pharma are pursuing. They also impact on glutamate but in ways that differ from the mGluR2 mechanism.
This author consults with leading institutions through GLG
Analyses are solely the work of the authors and have not been edited or endorsed by GLG.
